Abstract: 

During this session, Kerry Weinberg, Senior Data Scientist and Head of Data Science for Digital Health & Innovation at Amgen, will speak about how the company is pioneering the application of advanced data analytics techniques and digital tools that leverage emerging datasets to deliver on its mission to serve patients.

This talk will cover several opportunities and challenges when applying AI in the healthcare industry, and specifically in biotech, for patients with serious illness. Topics that will be explored include an overview of the opportunities to use machine learning and machine vision to predict patient outcomes, to better elucidate biological mechanisms driving patient response to therapy, to vectorize historical patient diagnoses to predict risk of developing a specific disease or illness in the future, and to improve patient adherence to treatment. Kerry will also expound upon the challenges faced when applying machine learning to biotech and biologically generated data. Attendees will learn about how Amgen – the world’s largest independent biotechnology company – is currently addressing these opportunities and overcoming challenges through the application of a variety of techniques (such as Bayesian network modeling, deep learning, etc.) on a multitude of diverse data sources (including genomic, health care records, etc.).

Kerry joined Amgen in 2016. In her current role, she leads Amgen Digital Health & Innovation’s Data Science team in utilizing machine learning to support Amgen’s mission to serve patients. Prior, she began her career at Beckman Coulter, where she honed her interest in biological systems engineering and modeling. Kerry received her BS and MS in Biological Engineering, as well as her MBA, from MIT.

Bio: 

Kerry Weinberg leads Data Sciences for Digital Health & Innovation at Amgen. Her team focuses on applying machine learning and artificial intelligence to improve Amgen’s agility, better reach patients, and improve digital health by better identifying patients, treating them, and enabling their adherence. Prior to this role, Kerry led AI strategy for Process Development at Amgen. Before joining Amgen, Kerry received her MBA and M.S. Biological Engineering from MIT as part of the Leaders for Global Operations Program. She previously led systems engineering efforts for high-speed cell sorters at Beckman Coulter. Kerry holds a B.S. Biological Engineering also from MIT.